{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:09:48Z","timestamp":1791234588239,"version":"4.1.0"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.canlet.2024.216782","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T22:28:06Z","timestamp":1709677686000},"page":"216782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Conquering chemoresistance in pancreatic cancer: Exploring novel drug therapies and delivery approaches amidst desmoplasia and hypoxia"],"prefix":"10.1016","volume":"588","author":[{"given":"Pavan Kumar","family":"Chintamaneni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Kiran S.S.","family":"Pindiprolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati Swagatika","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veera Venkata Satyanarayana Reddy","family":"Karri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Nesamony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvam","family":"Chelliah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2250-5830","authenticated-orcid":false,"given":"Mahendran","family":"Bhaskaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216782_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1049136","article-title":"Recent estimates and predictions of 5-year survival rate in patients with pancreatic cancer: a model-based period analysis","volume":"9","author":"Li","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.canlet.2024.216782_bib2","series-title":"Pancreatic Cancer","author":"Puckett","year":"2018"},{"key":"10.1016\/j.canlet.2024.216782_bib3","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.canlet.2024.216782_bib4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2217\/bmm.12.69","article-title":"Early diagnosis of pancreatic cancer: challenges and new developments","volume":"6","author":"Kaur","year":"2012","journal-title":"Biomarkers Med."},{"key":"10.1016\/j.canlet.2024.216782_bib5","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3389\/fendo.2018.00779","article-title":"Pancreatic cancer diagnosis and management: has the time come to prick the bubble?","volume":"9","author":"Moutinho-Ribeiro","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.canlet.2024.216782_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5958\/2278-4853.2021.01172.1","article-title":"Challenges in diagnosis of pancreatic cancer","volume":"10","author":"Jain","year":"2021","journal-title":"Asian Journal of Multidimensional Research"},{"key":"10.1016\/j.canlet.2024.216782_bib7","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.3390\/cancers6042137","article-title":"Desmoplasia and chemoresistance in pancreatic cancer","volume":"6","author":"Schober","year":"2014","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216782_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2020.07.041","article-title":"Hypoxia: Friend or foe for drug delivery in pancreatic cancer","volume":"492","author":"Shah","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216782_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876291","article-title":"Understanding tricky cellular and molecular interactions in pancreatic tumor microenvironment: new food for thought","volume":"13","author":"Agostini","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216782_bib10","first-page":"121","article-title":"Antifibrotic and tumor microenvironment modulating effect of date palm fruit (Phoenix dactylifera L.) extracts in pancreatic cancer","author":"Al Alawi","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2024.216782_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202000262","article-title":"Overcoming the tumor microenvironmental barriers of pancreatic ductal adenocarcinomas for achieving better treatment outcomes","volume":"4","author":"Alzhrani","year":"2021","journal-title":"Advanced Therapeutics"},{"key":"10.1016\/j.canlet.2024.216782_bib12","first-page":"9","article-title":"Targeting DNA repair, cell cycle, and tumor microenvironment in B cell lymphoma","author":"Br\u00f6ckelmann","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2024.216782_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100864","article-title":"Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance","volume":"64","author":"Capula","year":"2022","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2024.216782_bib14","series-title":"Targeting the Tumor Microenvironment, Current and Emerging Therapies in Pancreatic Cancer","first-page":"235","author":"Carnevale","year":"2017"},{"key":"10.1016\/j.canlet.2024.216782_bib15","series-title":"Smart Hypoxia-Responsive Transformable and Charge-Reversible Nanoparticles for the Deep Penetration and Tumor Microenvironment Modulation of Pancreatic Cancer","first-page":"287","author":"Chen","year":"2022"},{"key":"10.1016\/j.canlet.2024.216782_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1093240","article-title":"Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy","volume":"12","author":"Chen","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216782_bib17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.actbio.2023.05.047","article-title":"Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment","volume":"167","author":"Luo","year":"2023","journal-title":"Acta Biomater"},{"key":"10.1016\/j.canlet.2024.216782_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.actbio.2023.10.024","article-title":"Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer","volume":"173","author":"Yao","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.canlet.2024.216782_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3892\/or.2020.7859","article-title":"Platelet-derived growth factor-BB mediates pancreatic cancer malignancy via regulation of the Hippo\/Yes-associated protein signaling pathway","volume":"45","author":"Li","year":"2021","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2024.216782_bib20","article-title":"Advances of tumorigenesis, diagnosis at early stage, and cellular immunotherapy in gastrointestinal malignancies","volume":"11","author":"Zhu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216782_bib21","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1053\/j.gastro.2020.07.046","article-title":"Loss of HIF1A from pancreatic cancer cells increases expression of PPP1R1B and degradation of p53 to promote invasion and metastasis","volume":"159","author":"Tiwari","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2024.216782_bib22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2024.216782_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111798","article-title":"Metabolic reprogramming due to hypoxia in pancreatic cancer: implications for tumor formation, immunity, and more","volume":"141","author":"Hao","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2024.216782_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-021-01016-6","article-title":"Hypoxia promotes the metastasis of pancreatic cancer through regulating NOX4\/KDM5A-mediated histone methylation modification changes in a HIF1A-independent manner","volume":"13","author":"Li","year":"2021","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.canlet.2024.216782_bib25","first-page":"91","article-title":"The impact of hypoxia in pancreatic cancer invasion and metastasis","author":"Yuen","year":"2014","journal-title":"Hypoxia"},{"key":"10.1016\/j.canlet.2024.216782_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01030-w","article-title":"Targeting hypoxic tumor microenvironment in pancreatic cancer","volume":"14","author":"Tao","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216782_bib27","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1038\/s41388-018-0553-0","article-title":"The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer","volume":"38","author":"Jia","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2024.216782_bib28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fcell.2020.00287","article-title":"An FGFR\/AKT\/SOX2 signaling axis controls pancreatic cancer stemness","volume":"8","author":"Quan","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2024.216782_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.devcel.2019.07.022","article-title":"A Yap-Myc-Sox2-p53 regulatory network dictates metabolic homeostasis and differentiation in Kras-driven pancreatic ductal adenocarcinomas","volume":"51","author":"Murakami","year":"2019","journal-title":"Dev. Cell"},{"key":"10.1016\/j.canlet.2024.216782_bib30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.15252\/embj.201489574","article-title":"Antithetical NFAT c1\u2013Sox2 and p53\u2013miR200 signaling networks govern pancreatic cancer cell plasticity","volume":"34","author":"Singh","year":"2015","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2024.216782_bib31","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.canlet.2014.11.007","article-title":"MiR-1181 inhibits stem cell-like phenotypes and suppresses SOX2 and STAT3 in human pancreatic cancer","volume":"356","author":"Jiang","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216782_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2023.147288","article-title":"HIF1\u03b1 and HIF2\u03b1 regulate non-small-cell lung cancer dedifferentiation via expression of Sox2 and Oct4 under hypoxic conditions","volume":"863","author":"Xiong","year":"2023","journal-title":"Gene"},{"key":"10.1016\/j.canlet.2024.216782_bib33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2024.216782_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13578-017-0168-0","article-title":"TGF-\u03b2 in pancreatic cancer initiation and progression: two sides of the same coin","volume":"7","author":"Shen","year":"2017","journal-title":"Cell Biosci."},{"key":"10.1016\/j.canlet.2024.216782_bib35","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/1535-7163.MCT-07-0337","article-title":"A novel transforming growth factor \u03b2 receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis","volume":"7","author":"Melisi","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2024.216782_bib36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1039\/C9MD00447E","article-title":"Small molecule inhibitors in pancreatic cancer","volume":"11","author":"Sun","year":"2020","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.canlet.2024.216782_bib37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7555\/JBR.30.20150107","article-title":"Deciphering the role of hedgehog signaling in pancreatic cancer","volume":"30","author":"Gu","year":"2016","journal-title":"Journal of biomedical research"},{"key":"10.1016\/j.canlet.2024.216782_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.969731","article-title":"Fibroblast activation protein-based theranostics in pancreatic cancer","volume":"12","author":"Cheng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216782_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413408","article-title":"Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma: an update on heterogeneity and therapeutic targeting","volume":"22","author":"Vaish","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.216782_bib40","first-page":"2012","article-title":"Desmoplasia in pancreatic cancer. Can we fight it?","author":"Merika","year":"2012","journal-title":"Gastroenterology research and practice"},{"key":"10.1016\/j.canlet.2024.216782_bib41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10555-019-09799-0","article-title":"The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond","volume":"38","author":"Pastorekova","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.canlet.2024.216782_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2855-3","article-title":"Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms-Protocol of a first Ib\/IIa clinical trial","volume":"16","author":"Limani","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2024.216782_bib43","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00280-012-1852-8","article-title":"TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules","volume":"69","author":"Liu","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2024.216782_bib44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000503797","article-title":"Evolving treatment paradigms for pancreatic cancer","volume":"35","author":"Abbassi","year":"2019","journal-title":"Visc. Med."},{"key":"10.1016\/j.canlet.2024.216782_bib45","first-page":"45","article-title":"EZH2 downregulation augments the effect of irradiation in reducing pancreatic cancer cell proliferation in vitro","volume":"50","author":"Agrawal","year":"2020","journal-title":"ACLS (Ann. Clin. Lab. Sci.)"},{"key":"10.1016\/j.canlet.2024.216782_bib46","first-page":"16","article-title":"Novel therapeutics and preclinical imaging for pancreatic cancer - view from the lab","volume":"40","author":"Akerman","year":"2016","journal-title":"Cancer Forum"},{"key":"10.1016\/j.canlet.2024.216782_bib47","unstructured":"A.M. Abu-Dief, M. Alsehli, A. Al-Enizi, A. Nafady, Recent Advances in Mesoporous Silica Nanoparticles for Targeted Drug Delivery Applications."},{"key":"10.1016\/j.canlet.2024.216782_bib48","unstructured":"S. Agrawal, A. Garg, V. Varshney, Recent Updates on Applications of Lipid-Based Nanoparticles for Site-specific Drug Delivery."},{"key":"10.1016\/j.canlet.2024.216782_bib49","unstructured":"H. Alrbyawi, I. Poudel, M. Annaji, R.D. Arnold, A.K. Tiwari, R.J. Babu, Recent Advancements in Stimuli-Responsive Targeted Liposomal Formulations for Cancer Drug Delivery."},{"key":"10.1016\/j.canlet.2024.216782_bib50","unstructured":"2008, Nanoparticle therapeutics emerging treatment modalities in cancer.pdf."},{"key":"10.1016\/j.canlet.2024.216782_bib51","unstructured":"2009, Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers from concepts to clinic.pdf."},{"key":"10.1016\/j.canlet.2024.216782_bib52","series-title":"Multifunctional Systems for Combined Delivery, Biosensing and Diagnostics","first-page":"245","article-title":"Therapeutic nanoparticles for targeted delivery of anticancer drugs","author":"Alasvand","year":"2017"},{"key":"10.1016\/j.canlet.2024.216782_bib53","unstructured":"N.M. AlSawaftah, V. Paul, D. Kosaji, L. Khabbaz, N.S. Awad, G.A. Husseini, Ultrasound-sensitive cRGD-Modified Liposomes as a Novel Drug Delivery System."},{"key":"10.1016\/j.canlet.2024.216782_bib54","unstructured":"M. Daeihamed, S. Dadashzadeh, A. Haeri, M.F. Akhlaghi, Potential of Liposomes for Enhancement of Oral Drug Absorption."},{"key":"10.1016\/j.canlet.2024.216782_bib55","series-title":"Recent Advances in Lipid-Based Nanoformulations for Breast Cancer Theranostics","first-page":"175","author":"Pindiprolu","year":"2021"},{"key":"10.1016\/j.canlet.2024.216782_bib56","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2147\/DDDT.S261017","article-title":"Enhancement of antitumor efficacy of paclitaxel-loaded pegylated liposomes by n, n-dimethyl tertiary amino moiety in pancreatic cancer","volume":"14","author":"Chen","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.canlet.2024.216782_bib57","unstructured":"Z. Li, Q. Xu, X. Lin, K. Yu, L. Lin, Y. Liu, Z. Yu, T. Liu, D. Luo, Integrating of Lipophilic platinum(IV) Prodrug into Liposomes for Cancer Therapy on Patient-Derived Xenograft Model."},{"key":"10.1016\/j.canlet.2024.216782_bib58","unstructured":"D. Kong, W. Hong, M. Yu, Y. Li, Y. Zheng, X. Ying, Multifunctional Targeting Liposomes of Epirubicin Plus Resveratrol Improved Therapeutic Effect on Brain Gliomas."},{"key":"10.1016\/j.canlet.2024.216782_bib59","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1021\/acsnano.5b07781","article-title":"Irinotecan delivery by lipid-coated mesoporous silica nanoparticles shows improved efficacy and safety over liposomes for pancreatic cancer","volume":"10","author":"Liu","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.canlet.2024.216782_bib60","doi-asserted-by":"crossref","first-page":"19585","DOI":"10.18632\/aging.103918","article-title":"Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic cancer","volume":"12","author":"Mu","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.canlet.2024.216782_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202104594","article-title":"Remediating desmoplasia with EGFR-targeted photoactivable multi-inhibitor liposomes doubles overall survival in pancreatic cancer","volume":"9","author":"Obaid","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2024.216782_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14040713","article-title":"Microfluidics formulated liposomes of hypoxia activated prodrug for treatment of pancreatic cancer","volume":"14","author":"Shah","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.canlet.2024.216782_bib63","unstructured":"C. Liu, H. Chen, H. Zhou, S. Yu, Y. Zhao, N. Wang, W. Yao, A.H. Lu, W. Qiao, MRI-FI-guided Superimposed Stimulus-Responsive Co-assembled Liposomes for Optimizing Transmembrane Drug Delivery Pathways and Improving Cancer Efficacy."},{"key":"10.1016\/j.canlet.2024.216782_bib64","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.actbio.2019.09.003","article-title":"Synergistic cytotoxicity and co-autophagy inhibition in pancreatic tumor cells and cancer-associated fibroblasts by dual functional peptide-modified liposomes","volume":"99","author":"Chen","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.canlet.2024.216782_bib65","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2011.09.066","article-title":"In vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancer","volume":"157","author":"Kim","year":"2012","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2024.216782_bib66","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2019.05.018","article-title":"Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?","volume":"305","author":"Tang","year":"2019","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2024.216782_bib67","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nano.2015.08.007","article-title":"Simultaneous delivery of cytotoxic and biologic therapeutics using nanophotoactivatable liposomes enhances treatment efficacy in a mouse model of pancreatic cancer","volume":"12","author":"Tangutoori","year":"2016","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.canlet.2024.216782_bib68","unstructured":"K. Bhatt, P. Patil, P. Jani, P. Thakkar, K. Sawant, Design and Evaluation of Hyaluronic Acid-Coated PLGA Nanoparticles of Raloxifene Hydrochloride for Treatment of Breast Cancer."},{"key":"10.1016\/j.canlet.2024.216782_bib69","unstructured":"X. Yang, P. Shang, J. Ji, C. Malichewe, Z. Yao, J. Liao, D. Du, C. Sun, L. Wang, Y.j. Tang, X. Guo, Hyaluronic Acid-Modified Nanoparticles Self-Assembled from Linoleic Acid-Conjugated Chitosan for the Codelivery of miR34a and Doxorubicin in Resistant Breast Cancer."},{"key":"10.1016\/j.canlet.2024.216782_bib70","unstructured":"H. Ando, Y. Murakami, K. Eshima, T. Ishida, A Novel Polyethylene Glycol (PEG)-drug Conjugate of Venetoclax, a Bcl-2 Inhibitor, for Treatment of Acute Myeloid Leukemia (AML)."},{"key":"10.1016\/j.canlet.2024.216782_bib71","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.biopha.2018.03.101","article-title":"Evaluation of curcumin loaded chitosan\/PEG blended PLGA nanoparticles for effective treatment of pancreatic cancer","volume":"102","author":"Arya","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2024.216782_bib72","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1166\/jbn.2011.1238","article-title":"EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer","volume":"7","author":"Aggarwal","year":"2011","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.canlet.2024.216782_bib73","unstructured":"C. Ceci, P.M. Lacal, G. Graziani, Antibody-drug Conjugates: Resurgent Anticancer Agents with Multi-Targeted Therapeutic Potential."},{"key":"10.1016\/j.canlet.2024.216782_bib74","unstructured":"D. Sigorski, P. R\u00f3\u017canowski, E. I\u017cycka-\u015awieszewska, K. Wiktorska, Antibody\u2013Drug Conjugates in Uro-Oncology."},{"key":"10.1016\/j.canlet.2024.216782_bib75","unstructured":"A. Sommer, S. Berndt, H.G. Lerchen, S. Forveille, A. Sauvat, D. Mumberg, G. Kroemer, O. Kepp, Antibody\u2013drug Conjugates Harboring a Kinesin Spindle Protein Inhibitor with Immunostimulatory Properties."},{"key":"10.1016\/j.canlet.2024.216782_bib76","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/bc400490z","article-title":"Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system","volume":"25","author":"Zimmerman","year":"2014","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.canlet.2024.216782_bib77","unstructured":"S.K.S.S. Pindiprolu, P.T. Krishnamurthy, C. Dev, P.K. Chintamaneni, DR5 Antibody Conjugated Lipid-Based Nanocarriers of Gamma-Secretase Inhibitor for the Treatment of Triple Negative Breast Cancer."},{"key":"10.1016\/j.canlet.2024.216782_bib78","unstructured":"S. Tummala, M.N.S. Kumar, S.K. Pindiprolu, Improved Anti-tumor Activity of Oxaliplatin by Encapsulating in Anti-DR5 Targeted Gold Nanoparticles."},{"key":"10.1016\/j.canlet.2024.216782_bib79","unstructured":"S.K.S.S. Pindiprolu, P.T. Krishnamurthy, P.K. Chintamaneni, V.V.S.R. Karri, Nanocarrier Based Approaches for Targeting Breast Cancer Stem Cells."},{"key":"10.1016\/j.canlet.2024.216782_bib80","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.omto.2021.04.013","article-title":"Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy","volume":"21","author":"Zhang","year":"2021","journal-title":"Molecular Therapy-Oncolytics"},{"key":"10.1016\/j.canlet.2024.216782_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-022-02839-w","article-title":"Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model","volume":"22","author":"Wu","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.canlet.2024.216782_bib82","unstructured":"Y. Huo, L. Ma, M. Zhang, M. Niu, X. Gu, W. Zhang, M. Yan, G. Wei, Development of Anticancer Peptides with Low Hemolysis, High Penetrating Membrane Activity, Certain Analgesic Activity and the Synergistic Anticancer Effect."},{"key":"10.1016\/j.canlet.2024.216782_bib83","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: Historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.canlet.2024.216782_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0610-4","article-title":"Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide","volume":"7","author":"Lee","year":"2019","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.canlet.2024.216782_bib85","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.3390\/ijms21093218","article-title":"Pancreatic cancer and its microenvironment\u2014recent advances and current controversies","volume":"21","author":"Stopa","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.216782_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188895","article-title":"Exploration of tumor penetrating peptide iRGD as a potential strategy to enhance tumor penetration of cancer nanotherapeutics","author":"Saifi","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2024.216782_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.648187","article-title":"Fibroblast activation protein-\u03b1 as a target in the bench-to-bedside diagnosis and treatment of tumors: a narrative review","volume":"11","author":"Xin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216782_bib88","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/sj.onc.1206146","article-title":"Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers","volume":"22","author":"Miyamoto","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2024.216782_bib89","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.bjc.6602663","article-title":"Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells","volume":"93","author":"Wey","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216782_bib90","unstructured":"L. Zhu, J. Yang, Y. Ma, X. Zhu, C. Zhang, Aptamers Entirely Built from Therapeutic Nucleoside Analogues for Targeted Cancer Therapy."},{"key":"10.1016\/j.canlet.2024.216782_bib91","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2021.05.055","article-title":"Tumor-specific delivery of 5-fluorouracil\u2013incorporated epidermal growth factor receptor\u2013targeted aptamers as an efficient treatment in pancreatic ductal adenocarcinoma models","volume":"161","author":"Mahajan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2024.216782_bib92","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-020-01624-1","article-title":"Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma","volume":"15","author":"Li","year":"2020","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.canlet.2024.216782_bib93","unstructured":"J. Liu, T. Wei, J. Zhao, Y. Huang, H. Deng, A. Kumar, C. Wang, Z. Liang, X. Ma, X.J. Liang, Multifunctional Aptamer-Based Nanoparticles for Targeted Drug Delivery to Circumvent Cancer Resistance."},{"key":"10.1016\/j.canlet.2024.216782_bib94","doi-asserted-by":"crossref","first-page":"16539","DOI":"10.1021\/acsami.3c01967","article-title":"Aptamer and peptide-engineered polydopamine nanospheres for target delivery and tumor perfusion in synergistic chemo-phototherapy of pancreatic cancer","volume":"15","author":"Liu","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.canlet.2024.216782_bib95","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.cclet.2020.11.072","article-title":"A novel aptamer-based histochemistry assay for specific diagnosis of clinical breast cancer tissues","volume":"32","author":"Liu","year":"2021","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.canlet.2024.216782_bib96","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bbrc.2014.10.056","article-title":"A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis","volume":"454","author":"Kim","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2024.216782_bib97","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/nat.2012.0353","article-title":"Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells","volume":"22","author":"Ray","year":"2012","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.canlet.2024.216782_bib98","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1021\/nl500844m","article-title":"Improved in vitro efficacy of gold nanoconstructs by increased loading of G-quadruplex aptamer","volume":"14","author":"Dam","year":"2014","journal-title":"Nano Lett."},{"key":"10.1016\/j.canlet.2024.216782_bib99","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1021\/bm5001263","article-title":"AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA\u2013PCL\u2013pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy","volume":"15","author":"Lale","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.canlet.2024.216782_bib100","volume":"vol. 4","author":"Porciani","year":"2015"},{"key":"10.1016\/j.canlet.2024.216782_bib101","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/nat.2014.0516","article-title":"Alppl2 aptamer-mediated targeted delivery of 5-fluoro-2\u2032-deoxyuridine to pancreatic cancer","volume":"25","author":"Dua","year":"2015","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.canlet.2024.216782_bib102","doi-asserted-by":"crossref","first-page":"8360","DOI":"10.18632\/oncotarget.7073","article-title":"Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216782_bib103","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/mt.2016.60","article-title":"Targeted delivery of C\/EBP\u03b1-saRNA by pancreatic ductal adenocarcinoma-specific RNA aptamers inhibits tumor growth in vivo","volume":"24","author":"Yoon","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2024.216782_bib104","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.omtn.2019.08.017","article-title":"Targeted delivery of C\/EBP\u03b1-saRNA by RNA aptamers shows anti-tumor effects in a mouse model of advanced PDAC","volume":"18","author":"Yoon","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.canlet.2024.216782_bib105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.omtn.2016.11.008","article-title":"Aptamer-drug conjugates of active metabolites of nucleoside analogs and cytotoxic agents inhibit pancreatic tumor cell growth","volume":"6","author":"Yoon","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.canlet.2024.216782_bib106","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1158\/1541-7786.MCR-16-0462","article-title":"Blind SELEX approach identifies RNA aptamers that regulate EMT and inhibit metastasis","volume":"15","author":"Yoon","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216782_bib107","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.biochi.2017.09.006","article-title":"Selection of pd1\/pd-l1 x-aptamers","volume":"145","author":"Wang","year":"2018","journal-title":"Biochimie"},{"key":"10.1016\/j.canlet.2024.216782_bib108","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.omtn.2017.11.013","article-title":"Targeted delivery of auristatin-modified toxins to pancreatic cancer using aptamers","volume":"10","author":"Kratschmer","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.canlet.2024.216782_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201701070","article-title":"Sequentially triggered nanoparticles with tumor penetration and intelligent drug release for pancreatic cancer therapy","volume":"5","author":"He","year":"2018","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2024.216782_bib110","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.omtn.2018.06.003","article-title":"Gemcitabine-incorporated G-quadruplex aptamer for targeted drug delivery into pancreas cancer","volume":"12","author":"Park","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.canlet.2024.216782_bib111","doi-asserted-by":"crossref","first-page":"10760","DOI":"10.1021\/jacs.9b03720","article-title":"Elucidation and structural modeling of CD71 as a molecular target for cell-specific aptamer binding","volume":"141","author":"Wu","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.canlet.2024.216782_bib112","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1158\/1078-0432.CCR-21-3452","article-title":"Facts and hopes in immunotherapy of pancreatic cancer","volume":"28","author":"Bockorny","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216782_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693386","article-title":"AGIG chemo-immunotherapy in patients with advanced pancreatic cancer: a single-arm, single-center, phase 2 study","volume":"11","author":"Dai","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216782_bib114","first-page":"357","article-title":"Visualization analysis of bibliometrics on hot research topics in pancreatic cancer immunotherapy","volume":"32","author":"Du","year":"2023","journal-title":"Chin. J. Gen. Surg."},{"key":"10.1016\/j.canlet.2024.216782_bib115","doi-asserted-by":"crossref","first-page":"13168","DOI":"10.1021\/acsnano.2c06300","article-title":"Nanocarrier Co-formulation for delivery of a TLR7 agonist plus an immunogenic cell death stimulus triggers effective pancreatic cancer chemo-immunotherapy","volume":"16","author":"Luo","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.canlet.2024.216782_bib116","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1002\/cncr.27592","article-title":"Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase 1 trial","volume":"118","author":"Ocean","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2024.216782_bib117","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.11569\/wcjd.v29.i20.1151","article-title":"Current status of immunotherapy for pancreatic cancer","volume":"29","author":"Sun","year":"2021","journal-title":"World Chin. J. Dig."},{"key":"10.1016\/j.canlet.2024.216782_bib118","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202101208","article-title":"A tumor-penetrating nanomedicine improves the chemoimmunotherapy of pancreatic cancer","volume":"17","author":"Tong","year":"2021","journal-title":"Small"},{"key":"10.1016\/j.canlet.2024.216782_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103434","article-title":"Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy","volume":"28","author":"Elzoghby","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.canlet.2024.216782_bib120","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1039\/D0BM00916D","article-title":"Co-inhibition of the TGF-\u03b2 pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy","volume":"8","author":"Wang","year":"2020","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.canlet.2024.216782_bib121","first-page":"1","article-title":"Nanomedicine-mediated ubiquitination inhibition boosts antitumor immune response via activation of dendritic cells","author":"Wang","year":"2021","journal-title":"Nano Res."},{"key":"10.1016\/j.canlet.2024.216782_bib122","doi-asserted-by":"crossref","first-page":"27528","DOI":"10.1073\/pnas.2006186117","article-title":"Selective tumor antigen vaccine delivery to human CD169+ antigen-presenting cells using ganglioside-liposomes","volume":"117","author":"Affandi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2024.216782_bib123","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41467-017-01651-9","article-title":"Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression","volume":"8","author":"Lu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.216782_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120553","article-title":"Sequential receptor\u2013mediated mixed-charge nanomedicine to target pancreatic cancer, inducing immunogenic cell death and reshaping the tumor microenvironment","volume":"601","author":"Shen","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.canlet.2024.216782_bib125","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jconrel.2020.11.014","article-title":"Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors","volume":"330","author":"Lorkowski","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2024.216782_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.colcom.2021.100409","article-title":"PEGylated Mn containing MOF nanoparticles for potential immunotherapy of pancreatic cancer via manganese induced activation of anti-tumor immunity","volume":"42","author":"Liu","year":"2021","journal-title":"Colloid and Interface Science Communications"},{"key":"10.1016\/j.canlet.2024.216782_bib127","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41565-020-00822-y","article-title":"Nanomaterials for T-cell cancer immunotherapy","volume":"16","author":"Gong","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.canlet.2024.216782_bib128","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3390\/cancers11111627","article-title":"Myeloid-derived suppressor cells and pancreatic cancer: implications in novel therapeutic approaches","volume":"11","author":"Thyagarajan","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216782_bib129","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2024.216782_bib130","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2024.216782_bib131","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ymthe.2018.11.012","article-title":"Nanoparticle delivery of RIG-I agonist enables effective and safe adjuvant therapy in pancreatic cancer","volume":"27","author":"Das","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2024.216782_bib132","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.actbio.2021.05.002","article-title":"Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles","volume":"133","author":"Yu","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.canlet.2024.216782_bib133","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202101208","article-title":"A tumor\u2010penetrating nanomedicine improves the chemoimmunotherapy of pancreatic cancer","volume":"17","author":"Tong","year":"2021","journal-title":"Small"},{"key":"10.1016\/j.canlet.2024.216782_bib134","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.4049\/jimmunol.1801472","article-title":"LILRB1 blockade enhances bispecific T cell engager antibody\u2013induced tumor cell killing by effector CD8+ T cells","volume":"203","author":"Kim","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2024.216782_bib135","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nchembio839","article-title":"RNAi therapeutics: a potential new class of pharmaceutical drugs","volume":"2","author":"Bumcrot","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.canlet.2024.216782_bib136","doi-asserted-by":"crossref","first-page":"24560","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216782_bib137","unstructured":"Q. Li, X. Lv, C. Tang, C. Yin, Co-delivery of Doxorubicin and CRISPR\/Cas9 or RNAi-Expressing Plasmid by Chitosan-Based Nanoparticle for Cancer Therapy."},{"key":"10.1016\/j.canlet.2024.216782_bib138","unstructured":"J. Liu, L. Song, S. Liu, S. Zhao, Q. Jiang, B. Ding, A Tailored DNA Nanoplatform for Synergistic RNAi-\/Chemotherapy of Multidrug-Resistant Tumors."},{"key":"10.1016\/j.canlet.2024.216782_bib139","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bbrc.2023.03.056","article-title":"Adenovirus-mediated effects of Wnt and Notch signalling pathways on hair cell regeneration in mice","volume":"658","author":"Weng","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2024.216782_bib140","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-41251-9","article-title":"RNAi-mediated PD-L1 inhibition for pancreatic cancer immunotherapy","volume":"9","author":"Yoo","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2024.216782_bib141","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/hum.2014.072","article-title":"Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors","volume":"26","author":"Gayral","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.canlet.2024.216782_bib142","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1089\/ars.2011.4414","article-title":"Upsides and downsides of reactive oxygen species for Cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy","volume":"16","author":"Gupta","year":"2012","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.canlet.2024.216782_bib143","first-page":"1326","article-title":"A novel treatment strategy for pancreatic cancer based on gene profiles","volume":"43","author":"Hayashi","year":"2016","journal-title":"Jpn. J. Cancer Chemother."},{"key":"10.1016\/j.canlet.2024.216782_bib144","unstructured":"Y. Hu, Y. Sun, C. Wan, X. Dai, S. Wu, P.C. Lo, J. Huang, J.F. Lovell, H. Jin, K. Yang, Microparticles: Biogenesis, Characteristics and Intervention Therapy for Cancers in Preclinical and Clinical Research."},{"key":"10.1016\/j.canlet.2024.216782_bib145","unstructured":"J. Huang, C. Zhuang, J. Chen, X. Chen, X. Li, T. Zhang, B. Wang, Q. Feng, X. Zheng, M. Gong, Q. Gong, K. Xiao, K. Luo, W. Li, Targeted Drug\/Gene\/Photodynamic Therapy via a Stimuli-Responsive Dendritic-Polymer-Based Nanococktail for Treatment of EGFR-TKI-Resistant Non-small-cell Lung Cancer."},{"key":"10.1016\/j.canlet.2024.216782_bib146","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2019.07.012","article-title":"Notch signaling in breast cancer: from pathway analysis to therapy","volume":"461","author":"Krishna","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2024.216782_bib147","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/2472630318811108","article-title":"Pancreatic cancer gene therapy delivered by nanoparticles","volume":"24","author":"Kurtanich","year":"2019","journal-title":"SLAS Technology"},{"key":"10.1016\/j.canlet.2024.216782_bib148","article-title":"Visualization research on ENT1\/NIS dual-function gene therapy to reverse drug resistance mediated by MUC1 in GEM-resistant pancreatic cancer","volume":"120\u2013121","author":"Xi","year":"2023","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.canlet.2024.216782_bib149","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1021\/acs.biomac.1c01498","article-title":"Synthetic conjugated oligoelectrolytes are effective siRNA transfection carriers: Relevance to pancreatic cancer gene therapy","volume":"23","author":"Yang","year":"2022","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.canlet.2024.216782_bib150","doi-asserted-by":"crossref","first-page":"538","DOI":"10.7150\/thno.16684","article-title":"Current multistage drug delivery systems based on the tumor microenvironment","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2024.216782_bib151","unstructured":"D.R. Beckford Vera, S.D. Fontaine, H.F. VanBrocklin, B.R. Hearn, R. Reid, G.W. Ashley, D.V. Santi, PET Imaging of the EPR Effect in Tumor Xenografts Using Small 15 Nm Diameter Polyethylene Glycols Labeled with Zirconium-89."},{"key":"10.1016\/j.canlet.2024.216782_bib152","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1158\/1078-0432.CCR-16-0149","article-title":"Screening of conditionally reprogrammed patient-derived carcinoma cells identifies ERCC3-MYC interactions as a target in pancreatic cancer","volume":"22","author":"Beglyarova","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216782_bib153","series-title":"Methods in Enzymology, Elsevier","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/B978-0-12-391860-4.00006-9","article-title":"Multistage nanoparticles for improved delivery into tumor tissue","author":"Stylianopoulos","year":"2012"},{"key":"10.1016\/j.canlet.2024.216782_bib154","unstructured":"L. Fu, X. Hua, X. Jiang, J. Shi, Multistage Systemic and Cytosolic Protein Delivery for Effective Cancer Treatment."},{"key":"10.1016\/j.canlet.2024.216782_bib155","doi-asserted-by":"crossref","first-page":"34050","DOI":"10.1021\/acsami.8b14009","article-title":"Cascaded aptamers-governed multistage drug-delivery system based on biodegradable envelope-type nanovehicle for targeted therapy of HER2-overexpressing breast cancer","volume":"10","author":"Liang","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.canlet.2024.216782_bib156","unstructured":"F. Hu, C. Deng, Y. Zhou, Y. Liu, T. Zhang, P. Zhang, Z. Zhao, H. Miao, W. Zheng, W. Zhang, M. Wang, X. Ma, Multistage Targeting and Dual Inhibiting Strategies Based on Bioengineered Tumor Matrix Microenvironment-Mediated Protein Nanocages for Enhancing Cancer Biotherapy."},{"key":"10.1016\/j.canlet.2024.216782_bib157","unstructured":"Z. Liu, D. Zhou, L. Liao, pH\/Redox\/Lysozyme-Sensitive Hybrid Nanocarriers with Transformable Size for Multistage Drug Delivery."},{"key":"10.1016\/j.canlet.2024.216782_bib158","unstructured":"A. Sheikh, N.A. Alhakamy, S. Md, P. Kesharwani, Recent Progress of RGD Modified Liposomes as Multistage Rocket against Cancer."},{"key":"10.1016\/j.canlet.2024.216782_bib159","first-page":"1679","article-title":"Integrated strategy for identifying isoflavones in Belamcandae Rhizoma based on the combination of mass defect filtering and neutral-loss-triggered multistage fragmentation","author":"Yu","year":"2022","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.canlet.2024.216782_bib160","unstructured":"T. Zhao, C. Liang, Y. Zhao, X. Xue, Z. Ma, J. Qi, H. Shen, S. Yang, J. Zhang, Q. Jia, Q. Du, D. Cao, B. Xiang, H. Zhang, X. Qi, Multistage pH-Responsive Codelivery Liposomal Platform for Synergistic Cancer Therapy."},{"key":"10.1016\/j.canlet.2024.216782_bib161","doi-asserted-by":"crossref","first-page":"14698","DOI":"10.1039\/D3NR03161F","article-title":"Multifunctional GQDs for receptor targeting, drug delivery, and bioimaging in pancreatic cancer","volume":"15","author":"Shukla","year":"2023","journal-title":"Nanoscale"},{"key":"10.1016\/j.canlet.2024.216782_bib162","unstructured":"M. Creixell, N.A. Peppas, Co-delivery of siRNA and Therapeutic Agents Using Nanocarriers to Overcome Cancer Resistance."},{"key":"10.1016\/j.canlet.2024.216782_bib163","unstructured":"X. Dai, C. Tan, Combination of microRNA Therapeutics with Small-Molecule Anticancer Drugs: Mechanism of Action and Co-delivery Nanocarriers."},{"key":"10.1016\/j.canlet.2024.216782_bib164","unstructured":"I.U. Khan, R.U. Khan, H. Asif, Alamgeer, S.H. Khalid, S. Asghar, M. Saleem, K.U. Shah, S.U. Shah, S.A.A. Rizvi, Y. Shahzad, Co-delivery Strategies to Overcome Multidrug Resistance in Ovarian Cancer."},{"key":"10.1016\/j.canlet.2024.216782_bib165","unstructured":"Z.A. Lalami, F. Tafvizi, V. Naseh, M. Salehipour, Characterization and Optimization of Co-delivery Farnesol-Gingerol Niosomal Formulation to Enhance Anticancer Activities against Breast Cancer Cells."},{"key":"10.1016\/j.canlet.2024.216782_bib166","unstructured":"L. Pang, L. Zhang, H. Zhou, L. Cao, Y. Shao, T. Li, Reactive Oxygen Species-Responsive Nanococktail with Self-Amplificated Drug Release for Efficient Co-delivery of Paclitaxel\/Cucurbitacin B and Synergistic Treatment of Gastric Cancer."},{"key":"10.1016\/j.canlet.2024.216782_bib167","unstructured":"V. Patel, R. Lalani, I. Vhora, D. Bardoliwala, A. Patel, S. Ghosh, A. Misra, Co-delivery of Cisplatin and siRNA through Hybrid Nanocarrier Platform for Masking Resistance to Chemotherapy in Lung Cancer."},{"key":"10.1016\/j.canlet.2024.216782_bib168","article-title":"Gemcitabine and Pin1 siRNA co-delivery with fucoidan-coated nano-liposomes for therapy of pancreatic cancer","volume":"87","author":"Zheng","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.canlet.2024.216782_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122235","article-title":"Co-delivery of three synergistic chemotherapeutics in a core-shell nanoscale coordination polymer for the treatment of pancreatic cancer","volume":"301","author":"Jiang","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2024.216782_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122844","article-title":"Co-delivery of gemcitabine and Triapine by calcium carbonate nanoparticles against chemoresistant pancreatic cancer","volume":"636","author":"Zhao","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.canlet.2024.216782_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.100877","article-title":"Trap and kill strategy for non-BRCA mutant pancreatic cancer by co-delivery of olaparib and JQ1 with plectin-1 targeting peptide nanoparticles","volume":"33","author":"Wang","year":"2020","journal-title":"Nano Today"},{"key":"10.1016\/j.canlet.2024.216782_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.107053","article-title":"An oncolytic system produces oxygen selectively in pancreatic tumor cells to alleviate hypoxia and improve immune activation","volume":"199","author":"Chen","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2024.216782_bib173","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00432-018-2789-z","article-title":"Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols","volume":"145","author":"Abendroth","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216782_bib174","series-title":"Advances in Biological Regulation","article-title":"ABCC3 is a novel target for the treatment of pancreatic cancer","author":"Adamska","year":"2019"},{"key":"10.1016\/j.canlet.2024.216782_bib175","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrclinonc.2016.119","article-title":"Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer","volume":"13","author":"Adiseshaiah","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216782_bib176","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jbior.2017.11.007","article-title":"Molecular and cellular mechanisms of chemoresistance in pancreatic cancer","author":"Adamska","year":"2018","journal-title":"Advances in Biological Regulation"},{"key":"10.1016\/j.canlet.2024.216782_bib177","doi-asserted-by":"crossref","DOI":"10.21037\/cco.2017.11.02","article-title":"Targeting the stroma in pancreatic cancer","volume":"6","author":"Ahn","year":"2017","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216782_bib178","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1016\/j.bbagen.2012.11.004","article-title":"Monogalactosyl diacylglycerol, a replicative DNA polymerase inhibitor, from spinach enhances the anti-cell proliferation effect of gemcitabine in human pancreatic cancer cells","volume":"1830","author":"Akasaka","year":"2013","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.canlet.2024.216782_bib179","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003246","article-title":"High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege","volume":"9","author":"Ager","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524001757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524001757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:43:13Z","timestamp":1760816593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524001757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":179,"alternative-id":["S0304383524001757"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216782","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conquering chemoresistance in pancreatic cancer: Exploring novel drug therapies and delivery approaches amidst desmoplasia and hypoxia","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216782","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216782"}}